These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18768386)

  • 41. Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.
    Im D; Jung K; Yang S; Aman W; Hah JM
    Eur J Med Chem; 2015 Sep; 102():600-10. PubMed ID: 26318067
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Topoisomerase I-mediated DNA cleavage as a guide to the development of antitumor agents derived from the marine alkaloid lamellarin D: triester derivatives incorporating amino acid residues.
    Tardy C; Facompré M; Laine W; Baldeyrou B; García-Gravalos D; Francesch A; Mateo C; Pastor A; Jiménez JA; Manzanares I; Cuevas C; Bailly C
    Bioorg Med Chem; 2004 Apr; 12(7):1697-712. PubMed ID: 15028262
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
    Shallal HM; Russu WA
    Eur J Med Chem; 2011 Jun; 46(6):2043-57. PubMed ID: 21429632
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synthesis and evaluation of new antitumor 3-aminomethyl-4,11-dihydroxynaphtho[2,3-f]indole-5,10-diones.
    Shchekotikhin AE; Glazunova VA; Dezhenkova LG; Luzikov YN; Buyanov VN; Treshalina HM; Lesnaya NA; Romanenko VI; Kaluzhny DN; Balzarini J; Agama K; Pommier Y; Shtil AA; Preobrazhenskaya MN
    Eur J Med Chem; 2014 Oct; 86():797-805. PubMed ID: 25244612
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Generation of potent and selective kinase inhibitors by combinatorial biosynthesis of glycosylated indolocarbazoles.
    Sánchez C; Salas AP; Braña AF; Palomino M; Pineda-Lucena A; Carbajo RJ; Méndez C; Moris F; Salas JA
    Chem Commun (Camb); 2009 Jul; (27):4118-20. PubMed ID: 19568652
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synthesis, mode of action, and biological activities of rebeccamycin bromo derivatives.
    Moreau P; Anizon F; Sancelme M; Prudhomme M; Sevère D; Riou JF; Goossens JF; Hénichart JP; Bailly C; Labourier E; Tazzi J; Fabbro D; Meyer T; Aubertin AM
    J Med Chem; 1999 May; 42(10):1816-22. PubMed ID: 10346933
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Syntheses and antiproliferative activities of 7-azarebeccamycin analogues bearing one 7-azaindole moiety.
    Marminon C; Pierré A; Pfeiffer B; Pérez V; Léonce S; Joubert A; Bailly C; Renard P; Hickman J; Prudhomme M
    J Med Chem; 2003 Feb; 46(4):609-22. PubMed ID: 12570382
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of new fluorescent xanthines as kinase inhibitors.
    Kim D; Jun H; Lee H; Hong SS; Hong S
    Org Lett; 2010 Mar; 12(6):1212-5. PubMed ID: 20184370
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cyanopyridyl containing 1,4-dihydroindeno[1,2-c]pyrazoles as potent checkpoint kinase 1 inhibitors: improving oral biovailability.
    Tong Y; Przytulinska M; Tao ZF; Bouska J; Stewart KD; Park C; Li G; Claiborne A; Kovar P; Chen Z; Merta PJ; Bui MH; Olson A; Osterling D; Zhang H; Sham HL; Rosenberg SH; Sowin TJ; Lin NH
    Bioorg Med Chem Lett; 2007 Oct; 17(20):5665-70. PubMed ID: 17768051
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Kinase inhibitory potencies and in vitro antiproliferative activities of N-10 substituted pyrrolo[2,3-a]carbazole derivatives.
    Akué-Gédu R; Letribot B; Saugues E; Debiton E; Anizon F; Moreau P
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3807-9. PubMed ID: 22543026
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 1-(5-Chloro-2-alkoxyphenyl)-3-(5-cyanopyrazin-2-yl)ureas [correction of cyanopyrazi] as potent and selective inhibitors of Chk1 kinase: synthesis, preliminary SAR, and biological activities.
    Wang GT; Li G; Mantei RA; Chen Z; Kovar P; Gu W; Xiao Z; Zhang H; Sham HL; Sowin T; Rosenberg SH; Lin NH
    J Med Chem; 2005 May; 48(9):3118-21. PubMed ID: 15857116
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Synthesis and biological evaluation of novel phenylcarbazoles as potential anticancer agents.
    Routier S; Mérour JY; Dias N; Lansiaux A; Bailly C; Lozach O; Meijer L
    J Med Chem; 2006 Jan; 49(2):789-99. PubMed ID: 16420063
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis and identification of novel indolo[2,3-a]pyrimido[5,4-c]carbazoles as a new class of anti-cancer agents.
    Pierce LT; Cahill MM; Winfield HJ; McCarthy FO
    Eur J Med Chem; 2012 Oct; 56():292-300. PubMed ID: 22910137
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Structure-based design and synthesis of novel pseudosaccharine derivatives as antiproliferative agents and kinase inhibitors.
    Elsayed MS; El-Araby ME; Serya RA; El-Khatib AH; Linscheid MW; Abouzid KA
    Eur J Med Chem; 2013 Mar; 61():122-31. PubMed ID: 23063746
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis and in vitro antitumor activity of novel 2-alkyl-5-methoxycarbonyl-11-methyl-6H-pyrido[4,3-b]carbazol-2-ium and 2-alkylellipticin-2-ium chloride derivatives.
    Mori R; Kato A; Komenoi K; Kurasaki H; Iijima T; Kawagoshi M; Kiran YB; Takeda S; Sakai N; Konakahara T
    Eur J Med Chem; 2014 Jul; 82():16-35. PubMed ID: 24863982
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Carbazole Derivatives as Kinase-Targeting Inhibitors for Cancer Treatment.
    Ceramella J; Iacopetta D; Barbarossa A; Caruso A; Grande F; Bonomo MG; Mariconda A; Longo P; Carmela S; Sinicropi MS
    Mini Rev Med Chem; 2020; 20(6):444-465. PubMed ID: 31951166
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel tetracyclic benzo[b]carbazolones as highly potent and orally bioavailable ALK inhibitors: design, synthesis, and structure-activity relationship study.
    Jiang X; Zhou J; Ai J; Song Z; Peng X; Xing L; Xi Y; Guo J; Yao Q; Ding J; Geng M; Zhang A
    Eur J Med Chem; 2015 Nov; 105():39-56. PubMed ID: 26476749
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A comparative study of antitumor activities and DNA cleavage on a class of dehydroabietylamine derivatives.
    Liu CX; Lin ZX; Yu X; Lu Z; Zhou AM; Bao YL
    Pharmazie; 2013 Nov; 68(11):861-5. PubMed ID: 24380233
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A DNA binding indolocarbazole disaccharide derivative remains highly cytotoxic without inhibiting topoisomerase I.
    Qu X; Chaires JB; Ohkubo M; Yoshinari T; Nishimura S; Bailly C
    Anticancer Drug Des; 1999 Oct; 14(5):433-42. PubMed ID: 10766298
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors.
    N'gompaza-Diarra J; Bettayeb K; Gresh N; Meijer L; Oumata N
    Eur J Med Chem; 2012 Oct; 56():210-6. PubMed ID: 22982525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.